The authors assumed that patients with the Ims1 subtype are more suitable for RNA-based vaccination, as it was characterized by high levels of tumor mutational burden, suggesting that tumor mutations might generate immunogenic neoantigens and a high expression level of immune checkpoints (e.g., PD-1, CD40, PD-L1, CD80 and CD86) and ICD modulators (e.g., FPR1, CXCL10, ANXA1, and MET) (174, 175). Here, ANXA1 is linked to neoplasm.